A
Alcista
Alcista · 25%STVN
$30.64
Precio del escenario
$18.900
-0.344 (-1.82%)Al cierre
Loading chart…
- Máximo
- 19.270
- Apertura
- 19.270
- Precio medio ponderado por volumen
- 18.89
- Volumen
- 277.78K
- Capitalización
- 5.11B
- Mínimo
- 18.510
- Importe
- 5.25M
- EV/EBITDA, TTM
- 16.85
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Análisis de IA of Stevanato Group SpA (STVN)
MantenerStevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.
Métricas de valoración
El PER previsto actual de Stevanato Group SpA (STVN) es 29.15, frente a su media de 5 años de 35.49.
Escenarios de precio de Alphio AI para STVN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con STVN en cartera
Cronología de eventos
Noticias
2.008-05NASDAQ.COMStevanato (STVN) Q2 2026 Earnings Call Transcript
9.508-04seekingalphaStevanato Group Reports Strong Q2 Earnings with Strategic Divestiture
8.508-04NewsfilterStevanato Group Divests California Subsidiary Balda C. Brewer, Inc.
- 8.507-30Newsfilter
Stevanato Group Secures European Approvals for New Injector Therapies
- 9.507-21Newsfilter
Stevanato Group to Release Q2 2026 Financial Results
Preguntas frecuentes sobre STVN, respondidas por Alphio AI
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
Stevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.